The Global Assessment of Tafenoquine Hemolytic Risk (GATHER) randomized, controlled trial aimed to compare hemolytic risk among patients with normal G6PD enzyme activity and female patients with moderate G6PD deficiency (≥40 to <70% of the median value of G6PD enzyme activity among healthy male volunteers with normal G6PD activity, as determined at each trial site [hereafter, the site-specific normal value]). The gene discussed is G6PD; the disease is G6PD deficiency.